New drug aims to prevent dangerous platelet drop in breast cancer patients
NCT ID NCT07243418
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a drug called hetrombopag to see if it can prevent or reduce low platelet counts caused by antibody-drug conjugate (ADC) chemotherapy in breast cancer patients. The trial will include 72 adults aged 18-75. Researchers will measure how many patients develop severe low platelets during treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a radioactive tracer pinpoint Cancer's first stop?
- Can a personalized exercise program boost recovery in cancer survivors?
- Smartwatch could spot nerve damage before it starts
- Could ionized gas help fight breast cancer after surgery?
- Radiation may let breast cancer patients keep their nipple
- Can a smart digital program restore sleep for cancer survivors?